The vaccine proves safe in a small sample of human subjects, opening the way for the next phase of testing
A new colorectal cancer vaccine showed positive results in the phase 1 clinical trial to demonstrate that the approach is safe. The patients treated had no signs of serious adverse events and samples of their blood contained markers of immune activation — an early indication that the vaccine could activate immune cells to fight colorectal tumors and metastases. Further tests to determine if the vaccine is effective at slowing tumor growth are forthcoming.
The results were published in the Journal for ImmunoTherapy of Cancer.
Colon cancer, especially in younger people, is on the rise and is currently the second highest cause of cancer deaths in the US and worldwide. Surgery can cure the disease in many patients, but prognosis is poor for those with recurrence of their disease. If it proves effective in larger-scale trials the vaccine, developed by researchers at Jefferson (Philadelphia University + Thomas Jefferson University), could train the patient’s immune system to attack the colon cancer that had already spread before the surgery.
“There is an urgent need to understand what fuels colorectal cancer growth, and to harness that knowledge for developing novel therapies. This pivotal study provides some of the first evidence that it may be possible to safely direct a patient’s own immune system to seek and destroy this cancer type. This is a true milestone– made possible through the scientists and clinicians in our colorectal cancer team working in synchrony”, said Karen E. Knudsen, PhD, EVP of Oncology Services and Director of the Sidney Kimmel Cancer Center — Jefferson Health.
In earlier preclinical work in mice, Jefferson researchers demonstrated how the design of their vaccine worked. Tumor vaccines have historically been developed against a sort of molecular sign-post for cancer. Because they come from normal cells, cancer cells share nearly all of the same molecules, making it difficult for the immune system to differentiate normal from cancerous. Tumor antigens are molecules that the immune system can recognize as different from normal. In colorectal cancer, one such molecule called GUCY2C, was identified by Scott Waldman, MD, PhD, the Samuel M.V. Hamilton Professor and Director of the Gastrointestinal Cancer Program of the Sidney Kimmel Cancer Center — Jefferson Health.
The vaccine developed by first author, Adam Snook, PhD, Assistant Professor in the Department of Pharmacology and Experimental Therapeutics, Dr. Waldman and others, works by activating the immune system against the GUCY2C molecule. By joining the GUCY2C molecule with a molecule that boosts the immune reaction called PADRE, and loading it into an adenovirus vector, the researchers engineered a vaccine that could specifically target the colon cancer.
The current clinical trial enrolled 10 patients with stage I or II colon cancer. Patients were given one dose and came back for blood draws 30, 90, 180 days after immunization. Patients experienced some discomfort at the injection site, but reported no serious side effects of the vaccine. The blood samples showed activation of “killer T cells,” the immune cell type the researchers had expected. These killer T cells are responsible for finding and killing colon cancer cells that are responsible for causing the cancer to come back.
“We are preparing for a phase II study that will begin recruiting patients this fall,” says Dr. Snook. “We used lessons learned in the first study to modify the vaccine to hopefully make it even more effective.”
Since starting the trial, the researchers found that cancers other than colorectal cancer also express GUCY2C, including gastric, esophageal and pancreatic cancer. These are actually among the deadliest cancers. In fact, together with colorectal cancer, these four cancer types account for 20 percent of all cancer-related deaths.
“The goal of the study to begin this fall is to show that version 2.0 of the vaccine is even better and that it may benefit a much bigger group of the overall cancer patient population,” says Dr. Snook.
The Latest on: Colorectal cancer vaccine
via Google News
The Latest on: Colorectal cancer vaccine
- Saving girls from cervical cancer: HPV vaccine set to tame scourgeon October 17, 2019 at 7:04 pm
In 2012, the cancer recurred, in the colon this time. The part was cut off but it continued ... More than 800,000 10-year-old girls are set to receive two free doses of the Human Papilloma Virus ...
- New colorectal cancer vaccine may help pancreatic patients, tooon October 16, 2019 at 4:19 pm
PHILADELPHIA, Pa. (Ivanhoe Newswire) -- Surgery and chemotherapy have long been the primary treatment options for colorectal cancer. Even then, survival rates can be low if not detected early. Now, ...
- Over 1m doses of HPV vaccine stocked ahead of roll-out on Fridayon October 16, 2019 at 1:07 pm
The vaccine will be offered nationally alongside other routine infant vaccines through ... The leading cancers in incidence are lung, breast, prostate and colorectal cancer (6.1 per cent), while lung, ...
- Women should be screened for more than just breast cancer, local expert sayson October 15, 2019 at 1:36 pm
With just one vaccine, physicians can prevent 90% of cervical and anal cancers and genital ... Younger women also have very dense breast tissue, which can make it more difficult to see abnormalities ...
- University Hospital in Newark holds event offering free cancer screeningson October 12, 2019 at 6:29 am
There is also a community health fair being held at the hospital. The screenings available include breast and cervical cancer screenings, hepatitis C screenings, blood pressure checks, HPV vaccines, ...
- MHC class I dysfunction of glioma stem cells escapes from CTL-mediated immune response via activation of Wnt/β-catenin signaling pathwayon October 7, 2019 at 10:21 pm
Blocking CTLs-mediated killing decreased the anti-tumor effect of tumor lysate vaccine. The enhancement of T cells immune response resulting ... Effector memory T cells, early metastasis, and survival ...
- Americas Cancer Immunotherapy Market to Represent a Significant Expansion at 10.1% CAGR by 2023on October 3, 2019 at 6:30 pm
Americas Cancer Immunotherapy Market Research Report, By Cancer (Prostate, Colorectal, Head & Neck Cancer), By Therapeutics (Monoclonal Antibodies, Immune Checkpoint Inhibitors, Vaccines), By End ...
- Preventing cancer growth with a vaccine made of wrongly coded proteinson October 2, 2019 at 5:46 am
a genetic disorder that raises the risk of colorectal cancer. Neon Therapeutics showed that its neoantigen vaccine could boost the effectiveness of Bristol-Myers Squibb’s immuno-oncology drug Opdivo ...
- Imugene presents HER2 immuno-oncology vaccines success at ESMO ahead of 2020 studieson September 30, 2019 at 10:13 pm
Investigators found that when Imugene’s PD1-Vaxx was combined with B-Vaxx it was more effective in reducing tumour growth in a HER2 positive colon cancer model than in the PD1-Vaxx vaccine alone or in ...
- The company presents four scientific posters on its proprietary platform technology at the 2019 ESMO Annual Congresson September 26, 2019 at 2:15 am
with the PolyPEPI1018 cancer vaccine as an add-on to maintenance therapy in patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC). The results will be presented at the 2019 ...
via Bing News